Recovery and life span of 111indium‐radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S‐59) and ultraviolet A light

Authors:

Abstract
BACKGROUND:  A photochemical treatment (PCT) method to inactivate pathogens in platelet concentrates has been developed. The system uses a psoralen, amotosalen HCl, coupled with ultraviolet A (UVA) illumination.STUDY DESIGN AND METHODS:  Three sequential clinical trials evaluated viability of PCT platelets prepared with a prototype device. Posttransfusion recovery and lifespan of 111Indium‐labeled autologous 5 day‐old platelets in healthy subjects was assessed. In the first study, 23 subjects received transfusions of autologous PCT and/or control platelets. In a second study, 16 of these subjects received PCT platelets processed with a Compound Adsorption Device (CAD) (PCT‐CAD) to reduce patient exposure to residual amotosalen. In the third study, the effect of gamma‐irradiation on PCT platelets was studied. Data from control transfusions from Study A were used for paired comparisons in the latter 2 studies.RESULTS:  Mean PCT‐CAD platelet recovery for the 16 subjects with paired data was 42.5 ± 8.7% versus 50.3 ± 7.7% for control platelets, mean difference of 7.8% (p < 0.01). Mean lifespan for PCT‐CAD platelets was 4.8 days (±1.3) versus 6.0 days (±1.2) for control platelets, mean difference of 1.3 days (p < 0.01). Platelet recovery and lifespan were similar to PCT‐CAD for PCT without CAD treatment and PCT‐CAD with gamma‐irradiation.CONCLUSION:  Viability of 5 day‐old PCT platelets was less than for control platelets. However, both were within ranges reported for 5 day‐old platelets.

This publication has 32 references indexed in Scilit: